Filing Details

Accession Number:
0001209191-22-061760
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-16 21:41:51
Reporting Period:
2022-12-16
Accepted Time:
2022-12-16 21:41:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1724521 Arcus Biosciences Inc. RCUS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1671311 Jennifer Jarrett C/O Arcus Biosciences, Inc.
3928 Point Eden Way
Hayward CA 94545
Chief Operating Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-12-16 13,879 $30.66 150,212 No 4 S Direct
Common Stock Disposition 2022-12-16 2,603 $31.23 147,609 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $31.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. Includes 336 shares purchased on 11/30/2022 through the Company's Employee Stock Purchase Plan.
  4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.05 to $31.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.